
## Yuancheng Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5139433/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)â€ginsenoside Rh2 in MCFâ€7/Adr cells. British Journal of Pharmacology, 2012, 165, 120-134.	2.7	73
2	Synergistic killing by meropenem and colistin combination of carbapenem-resistant Acinetobacter baumannii isolates from Chinese patients in an in vitro pharmacokinetic/pharmacodynamic model. International Journal of Antimicrobial Agents, 2016, 48, 559-563.	1.1	42
3	Population Pharmacokinetics and Dosing Regimen Optimization of Meropenem in Cerebrospinal Fluid and Plasma in Patients with Meningitis after Neurosurgery. Antimicrobial Agents and Chemotherapy, 2016, 60, 6619-6625.	1.4	32
4	Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects. Journal of Infection, 2021, 82, 207-215.	1.7	24
5	Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects. Clinical Therapeutics, 2018, 40, 322-332.e5.	1.1	23
6	Model-based Evaluation of the Clinical and Microbiological Efficacy of Vancomycin: A Prospective Study of Chinese Adult In-house Patients. Clinical Infectious Diseases, 2018, 67, S256-S262.	2.9	18
7	Tolerability and Pharmacokinetics of Contezolid at Therapeutic and Supratherapeutic Doses in Healthy Chinese Subjects, and Assessment of Contezolid Dosing Regimens Based on Pharmacokinetic/Pharmacodynamic Analysis. Clinical Therapeutics, 2019, 41, 1164-1174.e4.	1.1	18
8	Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Antimicrobial Agents and Chemotherapy, 2021, 65, e0035021.	1.4	18
9	Evaluation of Meropenem Penetration into Cerebrospinal Fluid in Patients with Meningitis After Neurosurgery. World Neurosurgery, 2017, 98, 525-531.	0.7	16
10	Development and Validation of a New Ultra-Performance Liquid Chromatographic Method for Vancomycin Assay in Serum and Its Application to Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2014, 36, 175-181.	1.0	15
11	Enhanced bacterial killing with colistin/sulbactam combination against carbapenem-resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2021, 57, 106271.	1.1	15
12	Evaluation of the in vitro activity of levornidazole, its metabolites and comparators against clinical anaerobic bacteria. International Journal of Antimicrobial Agents, 2014, 44, 514-519.	1.1	13
13	Dose Optimization of Colistin Combinations against Carbapenem-Resistant Acinetobacter baumannii from Patients with Hospital-Acquired Pneumonia in China by Using an <i>In Vitro</i> Pharmacokinetic/Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	13
14	Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients. Clinical Therapeutics, 2020, 42, 818-829.	1.1	13
15	Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation. International Journal of Antimicrobial Agents, 2016, 47, 202-209.	1.1	11
16	An ultra-performance liquid chromatography–tandem mass spectrometry method to quantify vancomycin in human serum by minimizing the degradation product and matrix interference. Bioanalysis, 2019, 11, 941-955.	0.6	11
17	Evaluation of the Effect of Contezolid (MRX-I) on the Corrected QT Interval in a Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study in Healthy Chinese Volunteers. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	11
18	Sulbactam Enhances in vitro Activity of β-Lactam Antibiotics Against Acinetobacter baumannii. Infection and Drug Resistance, 2021, Volume 14, 3971-3977.	1.1	11

YUANCHENG CHEN

#	Article	IF	CITATIONS
19	Mechanism-Based Pharmacokinetic–Pharmacodynamic Modeling of Bidirectional Effect of Danshensu on Plasma Homocysteine in Rats. Pharmaceutical Research, 2009, 26, 1863-1873.	1.7	10
20	Tracking Cefoperazone/Sulbactam Resistance Development In vivo in A. baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome Sequencing. Frontiers in Microbiology, 2016, 7, 1268.	1.5	10
21	Optimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis. Future Microbiology, 2017, 12, 39-50.	1.0	10
22	Simultaneous separation and determination of vancomycin and its crystalline degradation products in human serum by ultra high performance liquid chromatography tandem mass spectrometry method and its application in therapeutic drug monitoring. Journal of Separation Science, 2020, 43, 3987-3994.	1.3	10
23	The Pharmacokinetic-Pharmacodynamic Model of Azithromycin for Lipopolysaccharide-Induced Depressive-Like Behavior in Mice. PLoS ONE, 2013, 8, e54981.	1.1	10
24	Pharmacokinetics and Disposition of Contezolid in Humans: Resolution of a Disproportionate Human Metabolite for Clinical Development. Antimicrobial Agents and Chemotherapy, 2021, 65, e0040921.	1.4	9
25	Quantification of levornidazole and its metabolites in human plasma and urine by ultra-performance liquid chromatography–mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 963, 119-127.	1.2	8
26	Rapid and Simultaneous Quantitation of Amoxicillin and Clavulanic Acid in Human Plasma and Urine by Ultra-Performance Liquid Chromatography Tandem Mass Spectrometry and Its Application to a Pharmacokinetic Study. Analytical Sciences, 2016, 32, 1269-1276.	0.8	8
27	Pharmacokinetics and pharmacodynamics of levofloxacin in bronchial mucosa and lung tissue of patients undergoing pulmonary operation. Experimental and Therapeutic Medicine, 2020, 20, 607-616.	0.8	8
28	In vitro bactericidal property of levornidazole against Bacteroides fragilis studied by time–kill assay and sigmoid E max model analysis. International Journal of Antimicrobial Agents, 2015, 45, 673-675.	1.1	7
29	Improved pharmacokinetic profile of levornidazole following intravenous infusion of 750mg every 24h compared with 500mg every 12h in healthy Chinese volunteers. International Journal of Antimicrobial Agents, 2016, 47, 224-228.	1.1	7
30	Determination of the sulfate and glucuronide conjugates of levornidazole in human plasma and urine, and levornidazole and its five metabolites in human feces by high performance liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1081-1082, 87-100.	1.2	7
31	Determination of DPâ€VPA and its active metabolite, VPA, in human plasma, urine, and feces by UPLC–MS/MS: A clinical pharmacokinetics and excretion study. Drug Testing and Analysis, 2019, 11, 1035-1047.	1.6	7
32	Pharmacokinetics of Nâ€ethylpentylone and its effect on increasing levels of dopamine and serotonin in the nucleus accumbens of conscious rats. Addiction Biology, 2020, 25, e12755.	1.4	7
33	Pharmacokinetic/Pharmacodynamic Based Breakpoints of Polymyxin B for Bloodstream Infections Caused by Multidrug-Resistant Gram-Negative Pathogens. Frontiers in Pharmacology, 2021, 12, 785893.	1.6	7
34	Concentration–response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent. Journal of Pharmacokinetics and Pharmacodynamics, 2019, 46, 531-541.	0.8	6
35	Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections. Antimicrobial Agents and Chemotherapy, 2022, 66, e0243021.	1.4	5
36	Association between Augmented Renal Clearance and Inadequate Vancomycin Pharmacokinetic/Pharmacodynamic Targets in Chinese Adult Patients: A Prospective Observational Study. Antibiotics, 2022, 11, 837.	1.5	5

YUANCHENG CHEN

#	Article	IF	CITATIONS
37	Development of an Liquid Chromatography–Tandem Mass Spectrometry Method for the Determination of Amoxicillin in Broth Medium and its Application to anIn VitroPharmacokinetic and Pharmacodynamic Model. Journal of Chromatographic Science, 2015, 54, bmv139.	0.7	4
38	In Vitro Anaerobic Pharmacokinetic/Pharmacodynamic Model to Simulate the Bactericidal Activity of Levornidazole Against Bacteroides fragilis. Clinical Therapeutics, 2017, 39, 828-836.	1.1	4
39	Pharmacokinetics and Pharmacodynamics of Levornidazole in Patients With Intra-abdominal Anaerobic Infection. Clinical Therapeutics, 2018, 40, 1548-1555.	1.1	4
40	Population Pharmacokinetics Study of Nemonoxacin Among Chinese Patients With Moderate Hepatic Impairment. Clinical Therapeutics, 2019, 41, 505-517.e0.	1.1	4
41	Pharmacokinetic and pharmacodynamic profiling of generic amphotericin B colloidal dispersion in a rat model of invasive candidiasis. Journal of Global Antimicrobial Resistance, 2020, 23, 113-119.	0.9	4
42	Pharmacokinetics and Pharmacodynamics of Nemonoxacin in a Neutropenic Murine Lung Infection Model Against Streptococcus Pneumoniae. Frontiers in Pharmacology, 2021, 12, 658558.	1.6	4
43	Polymyxin B Combined with Minocycline: A Potentially Effective Combination against blaOXA-23-harboring CRAB in In Vitro PK/PD Model. Molecules, 2022, 27, 1085.	1.7	4
44	Pharmacokinetics of benapenem for injection in subjects with mild to moderate renal impairment. European Journal of Clinical Pharmacology, 2022, 78, 1079-1086.	0.8	4
45	Pharmacokinetics, Safety and Pharmacokinetics/Pharmacodynamics Analysis of Omadacycline in Chinese Healthy Subjects. Frontiers in Pharmacology, 2022, 13, 869237.	1.6	4
46	Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against Acinetobacter baumannii in Patients with Hospital-Acquired Pneumonia. Antibiotics, 2022, 11, 703.	1.5	4
47	Pharmacokinetic-pharmacodynamic model of the antihypertensive interaction between telmisartan and hydrochlorothiazide in spontaneously hypertensive rats. Journal of Pharmacy and Pharmacology, 2014, 66, 1112-1121.	1.2	3
48	The pharmacokinetic–pharmacodynamic model of telmisartan and hydrochlorothiazide on blood pressure and plasma potassium after longâ€term administration in spontaneously hypertensive rats. Fundamental and Clinical Pharmacology, 2015, 29, 543-552.	1.0	3
49	Clinical Pharmacokinetics of Levornidazole in Elderly Subjects and Dosing Regimen Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis. Clinical Therapeutics, 2017, 39, 1336-1346.	1.1	3
50	Modeling Approach to Optimizing Dose Regimen of Vancomycin for Chinese Pediatric Patients with Gram-Positive Bacterial Infections. Frontiers in Pharmacology, 2021, 12, 648668.	1.6	3
51	Nemonoxacin dosage adjustment in patients with severe renal impairment based on population pharmacokinetic and pharmacodynamic analysis. British Journal of Clinical Pharmacology, 2021, 87, 4636-4647.	1.1	3
52	Regulatory utility of pharmacometrics in the development and evaluation of antimicrobial agents and its recent progress in China. CPT: Pharmacometrics and Systems Pharmacology, 2021, , .	1.3	2
53	Pharmacokinetics and Safety of Single-Dose Amphotericin B Colloidal Dispersion in Healthy Chinese Subjects and Population Pharmacokinetic/Pharmacodynamic Analysis to Inform Clinical Efficacy in Invasive Infections Caused by Candida albicans. Clinical Therapeutics, 2021, , .	1.1	2
54	Pharmacokinetics and Pharmacodynamics of Colistin Methanesulfonate in Healthy Chinese Subjects after Multi-Dose Regimen. Antibiotics, 2022, 11, 798.	1.5	2

#	Article	IF	CITATIONS
55	Pharmacokinetics of Levornidazole Tablet in Healthy Chinese Subjects and Proposed Dosing Regimen Based on Pharmacokinetic/Pharmacodynamic Analysis. Infectious Diseases and Therapy, 2021, 10, 911-923.	1.8	1
56	Comparative pharmacokinetics of amphotericin B after single- and multiple-dose administration of G-ABCD and conventional amphotericin B deoxycholate to rats. Journal of Global Antimicrobial Resistance, 2020, 22, 608-612.	0.9	0
57	Degradation of vancomycin in external quality assessment samples is a factor to underestimate its concentration. Bioanalysis, 2021, 13, 1743-1750.	0.6	Ο
58	Comparative assessment of pharmacokinetic parameters between HS016, an adalimumab biosimilar, and adalimumab (Humira®) in healthy subjects and ankylosing spondylitis patients: Population pharmacokinetic modeling. Advances in Clinical and Experimental Medicine, 2022, 31, 0-0.	0.6	0